ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Neogen (NEOG)
Neogen stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · NASDAQ
$12.47▲ +2.13%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Neogen in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Neogen
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Neogen a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $11.49 and $13.46; in 9 out of 10, between $9.99 and $15.48. Estimated annual volatility is 46%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $2.5B
- 52-week high
- $14.26
- 52-week low
- $5.37
- Revenue (12 months)
- $884M
- Revenue growth (YoY)
- -2.7%
- Gross margin
- 46.9%
- Operating margin
- -2.5%
- Net margin
- -0.9%
- Return on equity
- -2.7%
- Free cash flow (12 months)
- $40.9M
- Beta
- 0.00
What this means
ATLAS does not publish a fair value for NEOG right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks NEOG has traded between $5.37 and $14.26. Today it is 12.6% below that high and 132% above its low.
On the business: revenue fell 2.7% year over year; net margin is 0.9%.
Its beta is 0.00: it tends to move less than the market.
About the company
Neogen Corp. is a food and animal safety company that develops, manufactures, and markets diagnostic and testing solutions for regulated industries.
Want to see everything about Neogen?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Neogen do?
Neogen Corp. is a food and animal safety company that develops, manufactures, and markets diagnostic and testing solutions for regulated industries.
What is the chance NEOG goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, NEOG ends the month between $11.49 and $13.46.
How big is Neogen and what is its P/E ratio?
Neogen's market capitalization is $2.5B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is NEOG?
ATLAS estimates annual volatility at 46%. In a typical month, half of the outcomes end between $11.49 and $13.46.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer